KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2019 - 2025)

CRISPR Therapeutics AG's Other Operating Expenses history spans 9 years, with the latest figure at $53.7 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 415.53% year-over-year to $53.7 million; the TTM value through Dec 2025 reached $309.7 million, up 156.68%, while the annual FY2025 figure was $309.7 million, 156.68% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $53.7 million at CRISPR Therapeutics AG, down from $57.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $141.4 million in Q2 2025 and bottomed at $6.8 million in Q4 2022.
  • The 5-year median for Other Operating Expenses is $36.4 million (2022), against an average of $41.9 million.
  • The largest annual shift saw Other Operating Expenses plummeted 93.07% in 2022 before it soared 415.53% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $98.5 million in 2021, then tumbled by 93.07% to $6.8 million in 2022, then skyrocketed by 193.13% to $20.0 million in 2023, then plummeted by 47.92% to $10.4 million in 2024, then skyrocketed by 415.53% to $53.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Operating Expenses are $53.7 million (Q4 2025), $57.1 million (Q3 2025), and $141.4 million (Q2 2025).